VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. (Q37345045)
Jump to navigation
Jump to search
scientific article published on 05 July 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. |
scientific article published on 05 July 2012 |
Statements
1 reference
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. (English)
1 reference
L K Martin
1 reference
X Li
1 reference
B Kleiber
1 reference
E C Ellison
1 reference
M Bloomston
1 reference
M Zalupski
1 reference
T S Bekaii-Saab
1 reference
5 July 2012
1 reference
1 reference
2812-2820
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference